Table 3 Dose-response analysis regarding MRA use and mortality among PA patients.

From: Long term outcome of Aldosteronism after target treatments

 

Time varying number at mortality or censer-points

Incidence rate (per 1,000 person-years)

Adjusted HR (95%CI )

P

Daily dose of MRA (expressed as DDD/ Dose) *

 <0.17 (12.5 mg)

358

22.67

1.52 (1.18–1.96)

0.001

 0.17–0.66 (12.5–50 mg)

196

19.40

1 (ref.)

 

 >0.66 (50 mg)

59

17.47

1.57 (1.01–2.44)

0.044

  1. Abbreviations: CI, confidence interval; DDD, defined daily dose; HR, hazard ratio; MRA, mineralocorticoid receptor antagonist; PA, primary aldosteronism.
  2. *The DDD of MRA was calculated form 30 days to 365 days before mortality or the end of the study.
Back to article page